ESR2 and B-cell chronic lymphocytic leukemia: Agonists and estrogen analogues that activate ERβ can inhibit angiogenesis and cancer cell proliferation, suppressing cancer development, except in chronic lymphocytic leukemia (CLL) 151, 152.